In a mouse model of CML, we demonstrated that the combined administration of TKI and a PAI‐1 inhibitor significantly enhanced CML cell killing in the BM and prolonged CML mouse model survival.20 This evidence concerns the gene SERPINE1 and chronic myelogenous leukemia, BCR-ABL1 positive.